Company: DHR
Filing Date: 2025-04-22
Form Type: 10-Q
Source: 0000313616-25-000088
Chunk: 89

Company: DANAHER CORP /DE/
Filing Date: 2025-04-22
Form: 10-Q
Item: Item 8
Chunk 89
---
 were unfavorably impacted by:

•First quarter 2025 impairment charge related to a facility in the Biotechnology segment - 90 basis points

Depreciation and amortization of intangible assets as a percentage of sales decreased during the three-month period ended March 28, 2025 as compared to the comparable period of 2024, primarily as a result of the increase in sales.

LIFE SCIENCES

The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies.  Additionally, the segment provides products and consumables used to filter and remove contaminants from a variety of liquids and gases in many end-market applications.

Life Sciences Selected Financial Data 

 Three-Month Period Ended($ in millions)March 28, 2025March 29, 2024Sales$1,680 $1,745 Operating profit201 235 Depreciation45 38 Amortization of intangible assets149 141 Operating profit as a % of sales12.0 %13.5 %Depreciation as a % of sales2.7 %2.2 %Amortization as a % of sales8.9 %8.1 %

Sales Decline and Core Sales Decline

% Change Three-Month Period Ended March 28, 2025 vs. Comparable 2024 PeriodTotal sales decline (GAAP)(3.5)%Impact of:Acquisitions(2.0)%Currency exchange rates 1.5 %Core sales decline (non-GAAP)(4.0)%

25

Price increases in the segment did not have a significant impact on the change in sales on a year-over-year basis during the three-month period ended March 28, 2025 and are reflected as a component of core sales above.

Total segment sales decreased 3.5% during the three-month period ended March 28, 2025, primarily as a result of decreased core sales and to a lesser extent the impact of currency exchange rates, partially offset by acquisitions.  The year-over-year decrease in core sales in the three-month period was led by the genomics consumables business, primarily in North America.  The year-over-year core sales decline